It was a bumpy ride for ASX health stocks over the past week amid Trump's renewed threat to impose tariffs ... Read More The ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine (Seqirus) and plasma therapy (Behring) segments. Read why I rate CMXHF as a hold.

CSL put the following three initiatives in motion to reaccelerate its gross margins: 1) Donor mix management, 2) Improvement in plasma fixed cost per unit and 3) Improvement in efficiencies (such ...

We forecast an improvement in CSL’s operating margin to 32% by fiscal 2029 from 28% in fiscal 2024, a function of gross margin improvement stemming from product mix in CSL Behring and ...

CSL has four horses carrying its profit line: plasma collection volumes; extraction yields; selling prices; and input costs. Line them up correctly, and profits gallop. Unfortunately, the pandemic ...

Following a shareholder information meeting that updated stakeholders on performance and strategy, CSL (ASX:CSL) saw its share price rise by 5% over the past week. Despite the lack of specific ...

The CSL Limited (ASX: CSL) ... We will target a 5% improvement over the next 5 years, then a further 10% improvement on top of that by the back-end of the decade.

CSL Reaffirms FY25 Outlook October 28, 2024 — 08:36 pm EDT Written by RTTNews.com for RTTNews -> ...

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for ...